Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Atopic dermatitis may stem from poorly regulated sex hormones, study suggests

A study led by UT Southwestern dermatologists suggests that a common inflammatory skin condition may stem from poorly regulated sex hormones.

20 Sep 2021

SARS-CoV-2 antibody models describe differences between the kinetics of different antibodies

Researchers have created kinetic models of IgG and IgM anti-SARS-CoV-2 antibodies over 13.5 months following infection to understand long-lasting immunity better.

20 Sep 2021

Novel drug combinations improve progression-free survival for patients with advanced NSCLC

New findings from a large study led by researchers at Yale Cancer Center shows the addition of the drugs oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer (NSCLC).

18 Sep 2021

mAb treatment can rapidly select for SARS-CoV-2 resistance, suggests study

A study evaluates the efficacy of a mAb to prevent disease progression in non-hospitalized persons with symptomatic SARS-CoV-2 infection.

17 Sep 2021

SARS-CoV-2 variants show substantial differences in spike structure

To investigate the impact of these mutations, researchers performed cryo-electron microscopy analysis on the variants spike proteins to determine any structural changes.

15 Sep 2021

The comparative effectiveness of neutralizing monoclonal antibodies against SARS-CoV-2

A study investigated the comparative efficacy of neutralizing monoclonal antibodies against SARS-CoV-2.

13 Sep 2021

No evidence of pre-existing antibody and B cell immunity against SARS-CoV-2 in unexposed adults

A group of researchers analyzed the B cell response to SARS-CoV-2 in unexposed individuals.

10 Sep 2021

Novel combination therapy may prolong viral suppression in patients with HIV

A novel combination treatment may increase the ability of monoclonal antibodies to control viral infection in patients diagnosed with HIV, according to a Northwestern Medicine study published in Science Translational Medicine.

9 Sep 2021

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

A new study successfully identifies a series of inhibitors that possesses pancoronavirus activity against SARS-CoV, SARS-CoV-2, and MERS-CoV.

7 Sep 2021

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

In a recent study, scientists attempt to understand persistent COVID-19 and its implications in patients with hematologic malignancies.

6 Sep 2021

Post-exposure prophylaxis with monoclonal antibodies may reduce health system burden in the US

In a study conducted at the University of Washington, USA, the researchers assert that post-exposure prophylaxis with monoclonal antibodies could improve the clinical outcomes and health system costs regarding coronavirus disease (COVID-19). The study is currently available on the medRxiv* preprint server.

6 Sep 2021

Research uncovers test to identify iMCD patients with superior response to FDA-approved treatment

New research has uncovered a precision medicine test using blood proteins to identify a novel patient subgroup of idiopathic multicentric Castleman disease (iMCD), a rare blood disorder, who are more likely to respond to siltuximab, the only FDA approved treatment for the disease.

2 Sep 2021

New candidate vaccine for COVID-19 found to be efficacious in preclinical models

More than a year after the start of the COVID-19 pandemic, several vaccines have been authorized thanks to unprecedented worldwide research efforts. These first-generation vaccines bring great hope and are a mainstay in fighting the virus.

1 Sep 2021

Development of SARS-CoV-2 antibody escape variants in an immunocompromised individual

A new study published in mBio discusses the microevolution of SARS-CoV-2.

31 Aug 2021

Monoclonal antibody treatment combo can reduce the impact of COVID-19 in high-risk patients

In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab - two monoclonal antibody treatments under Food and Drug Administration emergency use authorization - keep high-risk patients out of the hospital when infected with mild to moderate COVID-19. The findings appear in The Lancet's EClinicalMedicine.

31 Aug 2021

ACTG announces positive data for monoclonal antibody combination therapy from the ACTIV-2 study

The AIDS Clinical Trials Group, the largest global HIV research network, which has expanded its focus to include evaluating outpatient treatment for COVID-19, today announced positive data for the monoclonal antibody combination therapy BRII-196/BRII-198 from the ACTIV-2 study of Outpatient Monoclonal Antibodies and Other Therapies.

27 Aug 2021

Persistence of Anti-PF4 levels in VITT patients four months after AstraZeneca COVID-19 vaccine

A study published on medRxiv* preprint server reported the over-time changes in the ability of the serum to activate platelets in vitro.

25 Aug 2021

Hot spots where covid vaccination lags push experimental antibody treatment

For months, Joelle Ruppert was among the millions of Americans who are covid vaccine holdouts. Her reluctance, she said, was not so much that she opposed the new vaccines but that she never felt "compelled" by the evidence supporting their experimental use.

25 Aug 2021

Non-invasive retinal imaging may be useful for detecting Alzheimer's disease risk

Amyloid plaques are protein deposits that collect between brain cells, hindering function and eventually leading to neuronal death.

23 Aug 2021

MHRA approves first monoclonal antibody treatment for COVID-19 in the UK

Following on from a thorough review of the evidence carried out by the MHRA, and recommendation by the Commission on Human Medicines (CHM), the government's independent expert scientific advisory body, the MHRA has approved Ronapreve as the first monoclonal antibody combination product indicated for use in the prevention and treatment of acute COVID-19 infection for the UK.

20 Aug 2021

Monoclonal Antibody News and Research

Further Reading

Atopic dermatitis may stem from poorly regulated sex hormones, study suggests

SARS-CoV-2 antibody models describe differences between the kinetics of different antibodies

Novel drug combinations improve progression-free survival for patients with advanced NSCLC

mAb treatment can rapidly select for SARS-CoV-2 resistance, suggests study

SARS-CoV-2 variants show substantial differences in spike structure

The comparative effectiveness of neutralizing monoclonal antibodies against SARS-CoV-2

No evidence of pre-existing antibody and B cell immunity against SARS-CoV-2 in unexposed adults

Novel combination therapy may prolong viral suppression in patients with HIV

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

Post-exposure prophylaxis with monoclonal antibodies may reduce health system burden in the US

Research uncovers test to identify iMCD patients with superior response to FDA-approved treatment

New candidate vaccine for COVID-19 found to be efficacious in preclinical models

Development of SARS-CoV-2 antibody escape variants in an immunocompromised individual

Monoclonal antibody treatment combo can reduce the impact of COVID-19 in high-risk patients

ACTG announces positive data for monoclonal antibody combination therapy from the ACTIV-2 study

Persistence of Anti-PF4 levels in VITT patients four months after AstraZeneca COVID-19 vaccine

Hot spots where covid vaccination lags push experimental antibody treatment

Non-invasive retinal imaging may be useful for detecting Alzheimer's disease risk

MHRA approves first monoclonal antibody treatment for COVID-19 in the UK

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®